Big Pharma's Role-Reversal in Licensing
Executive Summary
1998 saw a significant leveling off in Big Pharma's licensing spending, as many players were too preoccupied with mergers and restructuring to pay much attention to in-licensing opportunities. Alliance watch tracks total alliance dollar volume by development phase from 1995-1998.